Tuesday, May 14, 2024

egnite, Inc. Announces A.I. Partnership with Leading Physicians to Elevate the Standard of Care for Patients with Cardiovascular Disease

egnite, a digital healthcare company, announces a partnership with leading physicians from Morristown’s Gagnon Cardiovascular Institute, Philippe Généreux, a Director of the Structural Heart Program, and Linda Gillam, Chair of Cardiovascular Medicine. This partnership aims to elevate the standard of care for patients with cardiovascular (CV) disease, which affects an estimated 126 million adults in the U.S. and is expected to increase by 30% by 2060.

The partnership will spearhead research initiatives to better understand optimal points of therapeutic intervention for patients with valvular heart disease, using egnite’s flagship digital health platform, CardioCare. This initiative furthers the use of precision medicine algorithms to help physicians design and deliver an individualized patient management plan.

Also Read: Feinstein Institutes report on early mapping of vagus nerve, unveil novel stimulator for bioelectronic medicine research

“CardioCare’s AI tools will help us ensure that every patient receives optimal evaluation and management of their heart disease,” says Gillam, adding, “Its big data approach will also help us identify patients who might be candidates for one of many research trials, thereby potentially giving patients access to otherwise unavailable therapeutic options.”

“We are honored to be partnering with Doctors Gillam and Généreux, and working with physicians of this caliber will help us accelerate our platform’s innovation,” said Joel Portice, president and CEO of egnite.

The partnership will also support the expansion of Dr. Généreux’s staging research, which examines the value of cardiac staging relating to the treatment and outcomes of AS & MR using the 12 million de-identified cardiovascular encounters in egnite’s database.

“I am thrilled to collaborate with egnite’s team and use their incredible platform to better understand valve disease, build meaningful research, and improve patient management and outcomes,” said Généreux.

SOURCE: Businesswire

Subscribe Now

    Hot Topics